Shopping Cart 0
Cart Subtotal
USD 0

osteoarthritis-pipeline review, h2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Osteoarthritis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).

-The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Osteoarthritis-Overview 7

Osteoarthritis-Therapeutics Development 8

Osteoarthritis-Therapeutics Assessment 21

Osteoarthritis-Companies Involved in Therapeutics Development 31

Osteoarthritis-Drug Profiles 61

Osteoarthritis-Dormant Projects 213

Osteoarthritis-Discontinued Products 219

Osteoarthritis-Product Development Milestones 221

Appendix 229


List Of Figure

List of Figures

Number of Products under Development for Osteoarthritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Osteoarthritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Osteoarthritis-Pipeline by 4P-Pharma SAS, H2 2017

Osteoarthritis-Pipeline by AbbVie Inc, H2 2017

Osteoarthritis-Pipeline by Abiogen Pharma SpA, H2 2017

Osteoarthritis-Pipeline by Ablynx NV, H2 2017

Osteoarthritis-Pipeline by Amgen Inc, H2 2017

Osteoarthritis-Pipeline by Amura Holdings Ltd, H2 2017

Osteoarthritis-Pipeline by Anterogen Co Ltd, H2 2017

Osteoarthritis-Pipeline by Asahi Kasei Pharma Corp, H2 2017

Osteoarthritis-Pipeline by Axsome Therapeutics Inc, H2 2017

Osteoarthritis-Pipeline by Biopharm GmbH, H2 2017

Osteoarthritis-Pipeline by Bone Therapeutics SA, H2 2017

Osteoarthritis-Pipeline by Can-Fite BioPharma Ltd, H2 2017

Osteoarthritis-Pipeline by Cardax Inc, H2 2017

Osteoarthritis-Pipeline by Cellular Biomedicine Group Inc, H2 2017

Osteoarthritis-Pipeline by Corestem Inc, H2 2017

Osteoarthritis-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Osteoarthritis-Pipeline by Eli Lilly and Company, H2 2017

Osteoarthritis-Pipeline by Evgen Pharma Plc, H2 2017

Osteoarthritis-Pipeline by Galapagos NV, H2 2017

Osteoarthritis-Pipeline by Gemphire Therapeutics Inc, H2 2017

Osteoarthritis-Pipeline by Genequine Biotherapeutics GmbH, H2 2017

Osteoarthritis-Pipeline by GlaxoSmithKline Plc, H2 2017

Osteoarthritis-Pipeline by InKemia IUCT Group SA, H2 2017

Osteoarthritis-Pipeline by International Stem Cell Corp, H2 2017

Osteoarthritis-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Osteoarthritis-Pipeline by K-Stemcell Co Ltd, H2 2017

Osteoarthritis-Pipeline by Kang Stem Biotech Co Ltd, H2 2017

Osteoarthritis-Pipeline by Lateral Pharma Pty Ltd, H2 2017

Osteoarthritis-Pipeline by Levolta Pharmaceuticals Inc, H2 2017

Osteoarthritis-Pipeline by LG Chem, Ltd., H2 2017

Osteoarthritis-Pipeline by Marina Biotech Inc, H2 2017

Osteoarthritis-Pipeline by Medivir AB, H2 2017

Osteoarthritis-Pipeline by Merck KGaA, H2 2017

Osteoarthritis-Pipeline by Mesoblast Ltd, H2 2017

Osteoarthritis-Pipeline by Mor Research Application Ltd, H2 2017

Osteoarthritis-Pipeline by Nordic Bioscience A/S, H2 2017

Osteoarthritis-Pipeline by Novartis AG, H2 2017

Osteoarthritis-Pipeline by NovelMed Therapeutics Inc, H2 2017

Osteoarthritis-Pipeline by Osteologix Holdings Plc, H2 2017

Osteoarthritis-Pipeline by Pfizer Inc, H2 2017

Osteoarthritis-Pipeline by Pharmalink AB, H2 2017

Osteoarthritis-Pipeline by Philogen SpA, H2 2017

Osteoarthritis-Pipeline by PhytoHealth Corp, H2 2017

Osteoarthritis-Pipeline by PLx Pharma Inc, H2 2017

Osteoarthritis-Pipeline by ProteoThera Inc, H2 2017

Osteoarthritis-Pipeline by Regeneus Ltd, H2 2017

Osteoarthritis-Pipeline by Regulaxis SAS, H2 2017

Osteoarthritis-Pipeline by Rottapharm Biotech Srl, H2 2017

Osteoarthritis-Pipeline by Samumed LLC, H2 2017

Osteoarthritis-Pipeline by Seikagaku Corp, H2 2017

Osteoarthritis-Pipeline by Stelis Biopharma Pvt Ltd, H2 2017

Osteoarthritis-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Osteoarthritis-Pipeline by TissueGene Inc, H2 2017

Osteoarthritis-Pipeline by Traverse Biosciences Inc, H2 2017

Osteoarthritis-Pipeline by Unity Biotechnology Inc, H2 2017

Osteoarthritis-Pipeline by Yooyoung Pharm Co Ltd, H2 2017

Osteoarthritis-Pipeline by Yuhan Corp, H2 2017

Osteoarthritis-Pipeline by Yungjin Pharm Co Ltd, H2 2017

Osteoarthritis-Pipeline by Zimmer Biomet Holdings Inc, H2 2017

Osteoarthritis-Dormant Projects, H2 2017

Osteoarthritis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Osteoarthritis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Osteoarthritis-Dormant Projects, H2 2017 (Contd..3), H2 2017

Osteoarthritis-Dormant Projects, H2 2017 (Contd..4), H2 2017

Osteoarthritis-Dormant Projects, H2 2017 (Contd..5), H2 2017

Osteoarthritis-Discontinued Products, H2 2017

Osteoarthritis-Discontinued Products, H2 2017 (Contd..1), H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

4P-Pharma SAS

AbbVie Inc

Abiogen Pharma SpA

Ablynx NV

Amgen Inc

Amura Holdings Ltd

Anterogen Co Ltd

Asahi Kasei Pharma Corp

Axsome Therapeutics Inc

Biopharm GmbH

Bone Therapeutics SA

Can-Fite BioPharma Ltd

Cardax Inc

Cellular Biomedicine Group Inc

Corestem Inc

Dong-A Socio Holdings Co Ltd

Eli Lilly and Company

Evgen Pharma Plc

Galapagos NV

Gemphire Therapeutics Inc

Genequine Biotherapeutics GmbH

GlaxoSmithKline Plc

InKemia IUCT Group SA

International Stem Cell Corp

Jeil Pharmaceutical Co Ltd

K-Stemcell Co Ltd

Kang Stem Biotech Co Ltd

Lateral Pharma Pty Ltd

Levolta Pharmaceuticals Inc

LG Chem, Ltd.

Marina Biotech Inc

Medivir AB

Merck KGaA

Mesoblast Ltd

Mor Research Application Ltd

Nordic Bioscience A/S

Novartis AG

NovelMed Therapeutics Inc

Osteologix Holdings Plc

Pfizer Inc

Pharmalink AB

Philogen SpA

PhytoHealth Corp

PLx Pharma Inc

ProteoThera Inc

Regeneus Ltd

Regulaxis SAS

Rottapharm Biotech Srl

Samumed LLC

Seikagaku Corp

Stelis Biopharma Pvt Ltd

Takeda Pharmaceutical Company Ltd

TissueGene Inc

Traverse Biosciences Inc

Unity Biotechnology Inc

Yooyoung Pharm Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zimmer Biomet Holdings Inc